Nuvalent (NUVL) CEO On The Future Of Cancer Treatments

Nuvalent is a clinical stage biopharma company that develops treatments for cancer patients. CEO James Porter weighs in on the FDA breakthrough therapy designation for NVL-655. The latest NUVL earnings report indicated an EPS of -$0.69.

======== Schwab Network ========
Empowering every investor and trader, every market day.

Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe
Download the iOS app - https://apps.apple.com/us/app/schwab-...
Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-...
Watch on Sling - https://watch.sling.com/1/asset/19192...
Watch on Vizio - https://www.vizio.com/en/watchfreeplu...
Watch on DistroTV - https://www.distro.tv/live/schwab-net...
Follow us on X –   / schwabnetwork  
Follow us on Facebook –   / schwabnetwork  
Follow us on LinkedIn -   / schwab-network  

About Schwab Network - https://schwabnetwork.com/about

#stocks #healthcare #cancer #investing #trading #stockmarket #wallstreet #money #finance #businessnews #news